{"id":"vaccination-pneumovax-23","safety":{"commonSideEffects":[{"rate":"20-50","effect":"Injection site pain, erythema, or swelling"},{"rate":"5-15","effect":"Fever"},{"rate":"5-10","effect":"Myalgia or arthralgia"},{"rate":"5-10","effect":"Headache"},{"rate":"5-10","effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"The vaccine contains purified capsular polysaccharide antigens from 23 different pneumococcal serotypes conjugated or presented to elicit both T-cell and B-cell immune responses. This generates protective antibodies and cellular immunity that prevent invasive pneumococcal disease including pneumonia, bacteremia, and meningitis caused by the included serotypes.","oneSentence":"PNEUMOVAX 23 is a polysaccharide vaccine that stimulates the immune system to produce antibodies against 23 serotypes of Streptococcus pneumoniae.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:54:08.030Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of invasive pneumococcal disease in adults and children ≥2 years of age"},{"name":"Prevention of pneumococcal pneumonia, bacteremia, and meningitis"}]},"trialDetails":[{"nctId":"NCT05569954","phase":"PHASE3","title":"Safety and Immunogenicity of V116 in Pneumococcal Vaccine-naïve Adults 50 Years of Age or Older (V116-010, STRIDE-10)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2022-11-07","conditions":"Pneumococcal Disease","enrollment":1484},{"nctId":"NCT04214444","phase":"PHASE3","title":"Evaluation of Prime-boost Anti-pneumococcal Vaccination in Patients With Diffuse Large B Cell Lymphoma Treated With Rituximab","status":"COMPLETED","sponsor":"University Hospital, Tours","startDate":"2020-07-03","conditions":"Pneumococcal Infections, Lymphoma, Large B-Cell, Diffuse","enrollment":26},{"nctId":"NCT06800261","phase":"PHASE1","title":"Clinical Trial of PCV24 in Infants Aged 2-23 Months","status":"RECRUITING","sponsor":"Sinovac Life Sciences Co., Ltd.","startDate":"2025-05-08","conditions":"Pneumococcal Infectious Disease","enrollment":180},{"nctId":"NCT07333352","phase":"PHASE2","title":"PCV24 Clinical Trial in Infants and Young Children Aged 2 Months (Minimum 6 Weeks) to 71 Months","status":"RECRUITING","sponsor":"Shanghai Reinovax Biologics Co.,LTD","startDate":"2025-09-11","conditions":"Pneumococcal Infectious Disease","enrollment":480},{"nctId":"NCT05417165","phase":"PHASE2","title":"Anti-pneumococcal Vaccine Strategy in Patients With Chronic Lymphocytic Leukemia","status":"RECRUITING","sponsor":"Seema Bhat","startDate":"2023-09-29","conditions":"Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma","enrollment":80},{"nctId":"NCT06675032","phase":"PHASE1","title":"Phase I Clinical Trial of PCV24 in Children Aged 2 Months (Minimum 6 Weeks) to 17 Years","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shanghai Reinovax Biologics Co.,LTD","startDate":"2024-04-27","conditions":"Pneumococcal Infectious Disease","enrollment":230},{"nctId":"NCT06678620","phase":"PHASE2","title":"Phase II Clinical Trial of 24-valent Pneumococcal Polysaccharide Conjugate Vaccine","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shanghai Reinovax Biologics Co.,LTD","startDate":"2024-04-20","conditions":"Pneumococcal Infectious Disease","enrollment":992},{"nctId":"NCT03069703","phase":"PHASE2","title":"Innovative Anti-pneumococcal Vaccine Strategies in Patients With ANCA-associated Vasculitis Receiving Rituximab Therapy","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2018-02-05","conditions":"Invasive Pneumococcal Infection","enrollment":96},{"nctId":"NCT06838000","phase":"PHASE3","title":"Study of the Safety and Immunogenicity of Catch-up Vaccination With a 21-valent Pneumococcal Conjugate Vaccine (PCV21) in Healthy Infants, Toddlers, Children, and Adolescents","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2025-02-28","conditions":"Pneumococcal Infections","enrollment":1268},{"nctId":"NCT05155579","phase":"PHASE1","title":"Assessment of Safety and Immunogenicity of a Single Vial Presentation of R21/Matrix-M and Co-Administration With EPI Vaccines","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2022-05-14","conditions":"Malaria","enrollment":593},{"nctId":"NCT02126384","phase":"NA","title":"Identifocation the B Cell Subsets Responsible for Anti-pneumococcal Response","status":"COMPLETED","sponsor":"Institut National de la Santé Et de la Recherche Médicale, France","startDate":"2014-11-18","conditions":"Pneumococcal Diseases","enrollment":9},{"nctId":"NCT07142057","phase":"","title":"An Observational Study on the Impact of the 23-valent Pneumonia Vaccine on Lung Cancer Patients","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital of Guangzhou Medical University","startDate":"2025-09-01","conditions":"LUNG CANCER","enrollment":500},{"nctId":"NCT03104075","phase":"PHASE4","title":"Genomics and Epigenomics of the Elderly Response to Pneumococcal Vaccines","status":"COMPLETED","sponsor":"The Jackson Laboratory","startDate":"2017-04-17","conditions":"Pneumonia, Aging","enrollment":40},{"nctId":"NCT04460235","phase":"PHASE4","title":"Clinical Trial Assessing the Immunogenicity of an Anti-pneumococcal Vaccination Strategy (PCV13+PPV23 Versus PREVENAR20) in Adult Patients Treated for a Lymphoma","status":"RECRUITING","sponsor":"Poitiers University Hospital","startDate":"2021-09-07","conditions":"Vaccine, Streptococcus Pneumoniae, Lymphoma, Non-Hodgkin","enrollment":160},{"nctId":"NCT00622843","phase":"PHASE3","title":"Pneumococcal Conjugate Vaccination in HIV in Comparison to Polysaccharide Vaccine Boosting","status":"COMPLETED","sponsor":"Henry M. Jackson Foundation for the Advancement of Military Medicine","startDate":"2002-12","conditions":"HIV Infections, Streptococcus Pneumoniae","enrollment":275},{"nctId":"NCT06474377","phase":"PHASE1","title":"Clinical Trial of PCV24 in Adults","status":"COMPLETED","sponsor":"Sinovac Life Sciences Co., Ltd.","startDate":"2024-06-21","conditions":"Pneumococcal Infectious Disease","enrollment":170},{"nctId":"NCT06678607","phase":"PHASE1","title":"Phase I Clinical Trial of PCV24 in People Aged 18 Years and Older","status":"COMPLETED","sponsor":"Shanghai Reinovax Biologics Co.,LTD","startDate":"2023-11-19","conditions":"Pneumococcal Infectious Disease","enrollment":240},{"nctId":"NCT02637583","phase":"PHASE4","title":"Sequential Versus Simultaneous Pneumococcal Vaccination in Elderly: Immunological Memory and Antibody Levels","status":"COMPLETED","sponsor":"Jena University Hospital","startDate":"2017-10-18","conditions":"Pneumococcal Infections","enrollment":123},{"nctId":"NCT04481243","phase":"PHASE4","title":"A Study to Evaluate Pneumococcal Polysaccharide Vaccine Effectiveness in Children With Type 1 Diabetes","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2021-04-30","conditions":"Type 1 Diabetes","enrollment":29},{"nctId":"NCT06044077","phase":"PHASE3","title":"A Clinical Trial to Evaluate the Immunogenicity and Safety of the 23-valent Pneumococcal Polysaccharide Vaccine in Healthy People","status":"RECRUITING","sponsor":"Aimei Vacin BioPharm (Zhejiang) Co., Ltd.","startDate":"2023-09-08","conditions":"Pneumococcal Disease","enrollment":1920},{"nctId":"NCT05939219","phase":"NA","title":"Consistency, Immunogenicity, and Safety of Three Batches of 15-valent Pneumococcal Conjugate Vaccine","status":"UNKNOWN","sponsor":"Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd","startDate":"2023-07-01","conditions":"Healthy Volunteers","enrollment":2346},{"nctId":"NCT02255227","phase":"PHASE2","title":"Anti-pneumococcal Vaccine Strategy in Patients Treated With Immunosuppressants or Biotherapies for CIBD","status":"TERMINATED","sponsor":"Centre Hospitalier Universitaire de Saint Etienne","startDate":"2015-04-13","conditions":"Infections, Pneumococcal, Bowel Diseases, Inflammatory","enrollment":104},{"nctId":"NCT03921424","phase":"PHASE3","title":"Safety and Immunogenicity of V114 in Children Infected With Human Immunodeficiency Virus (HIV) (V114-030/PNEU-WAY PED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2019-11-05","conditions":"Pneumococcal Infections","enrollment":407},{"nctId":"NCT05316831","phase":"PHASE4","title":"Immune Response After Pneumococcal Vaccination in Patient With Chronic Lymphocytic Leukemia","status":"COMPLETED","sponsor":"Region Örebro County","startDate":"2019-01-01","conditions":"CLL, Vaccine Response","enrollment":77},{"nctId":"NCT03762824","phase":"PHASE4","title":"Combined Pneumococcal Conjugate and Polysaccharide Vaccination in Inflammatory Rheumatic Disease","status":"COMPLETED","sponsor":"Region Skane","startDate":"2016-06-14","conditions":"Rheumatoid Arthritis, Systemic Lupus, Sjögren Syndrome","enrollment":300},{"nctId":"NCT05346302","phase":"EARLY_PHASE1","title":"Persistent Readiness Through Early Prediction Immunization Study","status":"COMPLETED","sponsor":"Texas A&M University","startDate":"2022-02-08","conditions":"Inflammatory Response","enrollment":249},{"nctId":"NCT05481801","phase":"","title":"Adherence to Guidelines VAccination in Type 1 DIabetes Mellitus Patients (AVADI-2)","status":"COMPLETED","sponsor":"Castilla-La Mancha Health Service","startDate":"2022-09-01","conditions":"Type 1 Diabetes","enrollment":300},{"nctId":"NCT03885934","phase":"PHASE3","title":"Safety and Immunogenicity of Catch-up Vaccination Regimens of V114 (V114-024)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2019-06-25","conditions":"Pneumococcal Infections","enrollment":606},{"nctId":"NCT04974294","phase":"PHASE4","title":"PREVENTING PNEUMOcoccal Disease Through Vaccination (Study 2)","status":"UNKNOWN","sponsor":"Liverpool School of Tropical Medicine","startDate":"2021-07-28","conditions":"Streptococcus Pneumonia","enrollment":516},{"nctId":"NCT03873727","phase":"PHASE2","title":"Revaccination With PPS23 Boosted or Not by PCV13 in Splenectomised Patients.","status":"UNKNOWN","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2019-08-27","conditions":"Splenectomised Patients","enrollment":39},{"nctId":"NCT04168190","phase":"PHASE1, PHASE2","title":"A Phase 1/Phase 2 Study of Polyvalent Pneumococcal Conjugate Vaccine (V116) in Adults (V116-001)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2019-12-06","conditions":"Pneumonia, Pneumococcal","enrollment":600},{"nctId":"NCT02274415","phase":"PHASE2","title":"Immunogenicity Study of an Anti-pneumococcal Vaccination Strategy in Patients With Sickle Cells Disease","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2013-09-16","conditions":"Invasive Pneumococcal Infections, Sickle Cells Disease","enrollment":116},{"nctId":"NCT02707692","phase":"NA","title":"Perturbing of HIV Reservoir With Immune Stimulation","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2016-08","conditions":"AIDS, HIV","enrollment":54},{"nctId":"NCT05499351","phase":"PHASE4","title":"A Study of Booster Immunization With COVID-19 Vaccine,Inactivated Co -Administration With Influenza Vaccine and Pneumococcal Polysaccharide Vaccine","status":"COMPLETED","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2021-10-15","conditions":"COVID-19","enrollment":3000},{"nctId":"NCT04559204","phase":"PHASE4","title":"Evaluation of Safety and Immunogenicity of Combined Immunization of PPV23 and IIV4","status":"COMPLETED","sponsor":"China National Biotec Group Company Limited","startDate":"2020-09-11","conditions":"Influenza, Human, Pneumonia, Pneumococcal","enrollment":1224},{"nctId":"NCT05471531","phase":"PHASE4","title":"Study on Combined Vaccination With Quadrivalent Influenza Vaccine and 23-valent Pneumococcal Polysaccharide Vaccine","status":"COMPLETED","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2021-11-13","conditions":"Influenza and Pneumonia","enrollment":3000},{"nctId":"NCT02447718","phase":"PHASE4","title":"Vaccinating Children After Chemotherapy","status":"COMPLETED","sponsor":"Canadian Immunization Research Network","startDate":"2015-11-16","conditions":"Acute Lymphoblastic Leukemia","enrollment":156},{"nctId":"NCT03449459","phase":"EARLY_PHASE1","title":"Prevention of Acute Exacerbation in Subjects With COPD by Bacterial Decolonization in Lower Respiratory Tract","status":"COMPLETED","sponsor":"Shanghai Zhongshan Hospital","startDate":"2018-12-01","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":144},{"nctId":"NCT03480802","phase":"PHASE3","title":"A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults Infected With Human Immunodeficiency Virus (HIV) (V114-018)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-07-06","conditions":"Pneumococcal Infections","enrollment":302},{"nctId":"NCT00788151","phase":"PHASE2","title":"Study of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Peruvian Children Aged 2 to 11 Years","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2008-09-26","conditions":"Dengue Virus, Dengue Fever, Dengue Hemorrhagic Fever","enrollment":300},{"nctId":"NCT05298800","phase":"PHASE4","title":"Combined Immunization of COVID-19 Inactivated Vaccine With QIV and PPV23","status":"UNKNOWN","sponsor":"Centers for Disease Control and Prevention, China","startDate":"2021-10-08","conditions":"Safety, Immunogenicity, Vaccine, COVID-19 Vaccines","enrollment":3000},{"nctId":"NCT02547493","phase":"NA","title":"Vaccination Against Pneumococcal in Naïve Abatacept Rheumatoid Arthritis Patients","status":"COMPLETED","sponsor":"University Hospital, Montpellier","startDate":"2016-03-03","conditions":"Rheumatoid Arthritis","enrollment":80},{"nctId":"NCT00858728","phase":"NA","title":"Effect of Fruit and Vegetable Consumption on Immune Function in the Elderly","status":"COMPLETED","sponsor":"Queen's University, Belfast","startDate":"2006-10","conditions":"Immune Function","enrollment":83},{"nctId":"NCT00427895","phase":"PHASE3","title":"Study Comparing a 13-valent Pneumococcal Conjugate Vaccine With 23-valent Pneumococcal Polysaccharide Vaccine in Adults","status":"COMPLETED","sponsor":"Pfizer","startDate":"2007-02-27","conditions":"Pneumococcal Infections","enrollment":2141},{"nctId":"NCT03260790","phase":"PHASE4","title":"Pneumococcal Vaccines in Patients With Asthma","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2017-10-01","conditions":"Asthma","enrollment":17},{"nctId":"NCT03480763","phase":"PHASE3","title":"A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Healthy Adults 50 Years of Age or Older (V114-016/PNEU-PATH)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-06-22","conditions":"Pneumococcal Infections","enrollment":652},{"nctId":"NCT00013871","phase":"NA","title":"Pneumococcal Vaccine and Routine Pediatric Immunizations in HIV-Infected Children Receiving Anti-HIV Drugs","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections, Hepatitis B, Measles","enrollment":300},{"nctId":"NCT00001080","phase":"NA","title":"Effect of Vaccination on Turnover of Lamivudine (3TC) Sensitive and Resistant Virus Populations in HIV-1-Infected Individuals","status":"WITHDRAWN","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":""},{"nctId":"NCT04790851","phase":"PHASE4","title":"Evaluation of Immunogenicity and Safety of Combined Immunization of COVID-19 Vaccine (Produced in Beijing) and PPV23 / IIV4","status":"COMPLETED","sponsor":"China National Biotec Group Company Limited","startDate":"2021-03-10","conditions":"Influenza, Human, Pneumonia, Pneumococcal, Covid19","enrollment":1133},{"nctId":"NCT00023504","phase":"PHASE4","title":"Antibody Production in Immune Disorders","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2002-06-13","conditions":"Primary Immune Deficiency","enrollment":21},{"nctId":"NCT05079152","phase":"PHASE4","title":"Evaluation of Immunogenicity and Safety of Combined Immunization of COVAX (Produced in Wuhan) and PPV23 / IIV4","status":"UNKNOWN","sponsor":"China National Biotec Group Company Limited","startDate":"2021-05-06","conditions":"Influenza, Human, Pneumonia, Pneumococcal, COVID-19 Pneumonia","enrollment":1404},{"nctId":"NCT02279589","phase":"PHASE2","title":"Open Randomized Trial Evaluating Four Anti-pneumococcal Vaccine Strategies With Fractionated Doses of Non Conjugate Polysaccharide Vaccine to Prevent Hyporesponse in Healthy Volunteers","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2014-12-04","conditions":"Pneumococcal Infection","enrollment":60},{"nctId":"NCT04875858","phase":"PHASE4","title":"Immunogenicity After Revaccination With 23-valent Pneumococcal Polysaccharide Vaccine: Healthy Elderly People Versus Diabetic Patients","status":"UNKNOWN","sponsor":"Korea University Guro Hospital","startDate":"2021-05-01","conditions":"Pneumococcal Infections","enrollment":254},{"nctId":"NCT04875819","phase":"PHASE4","title":"Safety and Immunogenicity Following Meningococcal and Pneumococcal Immunization Among Adult People Living With HIV","status":"RECRUITING","sponsor":"Thomas Benfield","startDate":"2021-04-28","conditions":"Hiv, Meningococcal Infections, Pneumococcal Infections","enrollment":55},{"nctId":"NCT03802994","phase":"EARLY_PHASE1","title":"Pneumococcal Conjugate Vaccine in Aging Renal Transplant","status":"TERMINATED","sponsor":"VA Office of Research and Development","startDate":"2018-11-01","conditions":"Renal Transplantation, Aging","enrollment":57},{"nctId":"NCT03835975","phase":"PHASE3","title":"Trial to Evaluate the Safety and Immunogenicity of a 20-Valent Pneumococcal Vaccine in Adults 65 Years of Age or Older With Prior Pneumococcal Vaccination","status":"COMPLETED","sponsor":"Pfizer","startDate":"2019-02-12","conditions":"Pneumococcal Disease","enrollment":875},{"nctId":"NCT00213265","phase":"PHASE3","title":"Safety and Immunogenicity of 7-Valent Pneumococcal Conjugate Vaccine in Children Receiving Solid Organ Transplants","status":"COMPLETED","sponsor":"The Hospital for Sick Children","startDate":"2002-07","conditions":"Organ Transplant, Immunosuppression","enrollment":81},{"nctId":"NCT03547167","phase":"PHASE3","title":"A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults at Increased Risk for Pneumococcal Disease (V114-017/PNEU-DAY)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-07-16","conditions":"Pneumococcal Infections","enrollment":1515},{"nctId":"NCT03478254","phase":"","title":"Adherence to Guidelines VAccination in Type 1 DIabetes Mellitus Patients (AVADI-1).","status":"COMPLETED","sponsor":"Jesús Moreno Fernández","startDate":"2017-12-01","conditions":"Type 1 Diabetes Mellitus","enrollment":300},{"nctId":"NCT00907777","phase":"PHASE3","title":"Vaccination With GSK 1024850A in Children Primed With GSK 1024850A & Boosted With Pneumovax 23™","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-06-23","conditions":"Infections, Streptococcal, Streptococcus Pneumoniae","enrollment":52},{"nctId":"NCT02012309","phase":"NA","title":"Mechanisms of Impaired HIV-associated B Cell and Pneumococcal Vaccine Responses","status":"UNKNOWN","sponsor":"University of Colorado, Denver","startDate":"2014-08","conditions":"HIV, Pneumococcal Infections, Pneumococcal Vaccines","enrollment":60},{"nctId":"NCT00985751","phase":"PHASE2","title":"Safety & Immunogenicity of Pneumococcal Vaccine 2189242A in Children Aged 12-23 Months at the Time of First Vaccination","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-11-24","conditions":"Infections, Streptococcal","enrollment":257},{"nctId":"NCT04551248","phase":"","title":"Post-marketing Safety Evaluation of Pneumococcal Vaccines Among Children and Elderly Adults.","status":"UNKNOWN","sponsor":"Sungkyunkwan University","startDate":"2021-08-01","conditions":"Pneumococcal Vaccine Adverse Reaction","enrollment":1000000},{"nctId":"NCT01942174","phase":"PHASE3","title":"VACcination In Methotrexate Treated Rheumatoid Arthritis Patients","status":"COMPLETED","sponsor":"University Hospital, Montpellier","startDate":"2013-09-27","conditions":"Rheumatoid Arthritis","enrollment":276},{"nctId":"NCT03039491","phase":"EARLY_PHASE1","title":"Immune Response to Pneumococcal Vaccination in Aging HIV Positive Adults","status":"COMPLETED","sponsor":"Medical University of South Carolina","startDate":"2015-09-01","conditions":"HIV Lipodystrophy, Aging","enrollment":160},{"nctId":"NCT02717494","phase":"PHASE2","title":"Safety and Immunogenicity of Anti-Pneumococcal Vaccines in HIV-Infected Pregnant Women","status":"COMPLETED","sponsor":"Westat","startDate":"2016-03","conditions":"PNC Vaccine, HIV-infected Pregnant Women","enrollment":347},{"nctId":"NCT03056924","phase":"","title":"Immunogenicity of Influenza, Pneumococcal and Hepatitis B Vaccines in IBD Patients Treated With Vedolizumab","status":"COMPLETED","sponsor":"Boston Medical Center","startDate":"2017-07-05","conditions":"Inflammatory Bowel Diseases","enrollment":173},{"nctId":"NCT01175083","phase":"PHASE3","title":"Immunization of Children Between 8 Weeks and 2 Years of Age With GSK Pneumococcal Vaccine GSK1024850A","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-06-01","conditions":"Infections, Streptococcal","enrollment":300},{"nctId":"NCT00345358","phase":"PHASE3","title":"Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' 10-valent Pneumococcal Conjugate Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-09-18","conditions":"Infections, Streptococcal","enrollment":600},{"nctId":"NCT02260882","phase":"PHASE4","title":"Revaccination With PNEUMOVAX™ 23 in Older Japanese Adults (V110-902)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-10-31","conditions":"Pneumococcal Infection","enrollment":243},{"nctId":"NCT01153893","phase":"PHASE3","title":"Immunization of Children Previously Primed With GSK Pneumococcal Vaccine GSK1024850A and of Unprimed Children in Nigeria","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-10-04","conditions":"Infections, Streptococcal","enrollment":105},{"nctId":"NCT01924169","phase":"PHASE2","title":"Lenalidomide as Immune Adjuvant in Patient's With Chronic Lymphocytic Leukemia (CLL)","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2014-11-24","conditions":"Hematologic Disorder","enrollment":3},{"nctId":"NCT00758264","phase":"PHASE3","title":"Co-administration of Meningococcal Vaccine GSK134612 and Pneumococcal Vaccine GSK1024850A vs Individual Administration","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-10-30","conditions":"Infections, Meningococcal","enrollment":363},{"nctId":"NCT03514979","phase":"PHASE2","title":"Acquired Immunodeficiency in ANCA Associated Vasculitis","status":"UNKNOWN","sponsor":"Cambridge University Hospitals NHS Foundation Trust","startDate":"2018-06","conditions":"Systemic Vasculitis","enrollment":124},{"nctId":"NCT01944462","phase":"PHASE4","title":"Impact and Cost of a Pharmacist Pneumococcal Vaccination Program With PNEUMOVAX® 23 at an Urban Senior Center","status":"COMPLETED","sponsor":"Thomas Jefferson University","startDate":"2014-01","conditions":"Study is Open to Seniors Age 50 or Older","enrollment":203},{"nctId":"NCT00169234","phase":"PHASE1, PHASE2","title":"Pneumococcal Adult-dose Ranging Immunization Study","status":"COMPLETED","sponsor":"Kaiser Permanente","startDate":"2003-05","conditions":"Pneumonia","enrollment":220},{"nctId":"NCT02719379","phase":"PHASE1","title":"Immune Response to Pneumococcal Polysaccharide Vaccine (23-valent) Predicts Asthma Status and Outcomes in Late Adolescents With Asthma","status":"COMPLETED","sponsor":"Rohit Divekar","startDate":"2016-04","conditions":"Asthma","enrollment":60},{"nctId":"NCT01781871","phase":"PHASE4","title":"Immunogenicity of 13-valent Pneumococcal Conjugate Vaccine Compared to the Pneumococcal Polysaccharide Vaccine in Adult Kidney and Liver Transplant Patients","status":"COMPLETED","sponsor":"Helsinki University Central Hospital","startDate":"2013-01","conditions":"Kidney Transplantation, Liver Transplantation","enrollment":182},{"nctId":"NCT02097849","phase":"PHASE2","title":"Vaccination Response in Tecfidera-Treated Versus Interferon-Treated Participants With Relapsing Forms of Multiple Sclerosis.","status":"COMPLETED","sponsor":"Biogen","startDate":"2015-02-28","conditions":"Relapsing Forms of Multiple Sclerosis","enrollment":71},{"nctId":"NCT00169507","phase":"PHASE3","title":"Study of Immunological Memory Induced in Children by a Full 4 Dose Vaccination Schedule of 11 Valent Pneumococcal Conjugate Vaccine by Giving 1 Dose of Aventis Pasteur's 23-valent Pneumococcal Polysaccharide Vaccine (Pneumo 23)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-03","conditions":"Prophylaxis Pneumococcal Vaccine","enrollment":100},{"nctId":"NCT00535730","phase":"PHASE3","title":"ZOSTAVAX™ Administered Concomitantly With PNEUMOVAX™ 23 (V211-012)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-06","conditions":"Herpes Zoster, Pneumococcal Infection","enrollment":473},{"nctId":"NCT00560950","phase":"PHASE3","title":"Revaccination With PNEUMOVAX(TM) 23 in Older Adults (V110-007)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-07","conditions":"Pneumococcal Infection","enrollment":143},{"nctId":"NCT03095326","phase":"PHASE4","title":"Pneumococcal Vaccination for Splenectomised Thalassemia Major Patients in Indonesia","status":"COMPLETED","sponsor":"Fakultas Kedokteran Universitas Indonesia","startDate":"2013-09-01","conditions":"Thalassemia, Pneumococcal Infection","enrollment":56},{"nctId":"NCT00579345","phase":"PHASE3","title":"Second Extension Study to Evaluate Safety and Tolerability of Influenza Vaccines in Adults and Elderly, and to Evaluate Immunogenicity and Concomitant Vaccination With Pneumococcal Vaccine in a Subgroup","status":"COMPLETED","sponsor":"Novartis","startDate":"2007-10","conditions":"Influenza","enrollment":1522},{"nctId":"NCT02543918","phase":"PHASE1","title":"A Study of the Immune Response to Vaccines and Ixekizumab (LY2439821) in Healthy Participants","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2015-09","conditions":"Healthy","enrollment":84},{"nctId":"NCT00333450","phase":"PHASE3","title":"Immune Memory Evaluation in Children Following a Primary Vaccination With Pneumococcal Conjugate Vaccines.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-08","conditions":"Infections, Streptococcal","enrollment":120},{"nctId":"NCT00307567","phase":"PHASE2","title":"Multicentre Booster & Immune Memory Study of a Booster Dose of GSK Biologicals' 10-valent Pneumococcal Conjugate Vaccine or a Single Dose of 23-valent Plain Polysaccharide Vaccine in Healthy Children Aged 11-18 Mths, Previously Vaccinated in Study 103488","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-11","conditions":"Acellular Pertussis, Tetanus, Hepatitis B","enrollment":689},{"nctId":"NCT02806284","phase":"PHASE2","title":"Pneumococci and Hib Vaccination After Neurotrauma or Neurosurgery","status":"COMPLETED","sponsor":"Uppsala University","startDate":"2001-01","conditions":"Meningitis","enrollment":85},{"nctId":"NCT00589394","phase":"PHASE1","title":"Analysis of the Mechanisms of Protective Humoral Immunity in Response to the Pneumococcal Vaccine","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2007-07","conditions":"Healthy","enrollment":100},{"nctId":"NCT00741039","phase":"PHASE2","title":"Prospective Trial of Vaccine Responses Against Pneumococcus and Influenza in Adult Cancer Patients 65 Years of Age and Older","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2008-08","conditions":"Breast Cancer, Lung Cancer, Prostate Cancer","enrollment":126},{"nctId":"NCT01432158","phase":"PHASE3","title":"Pneumococcal Adult Kinetics Study - Understanding the B Cell Response to Pneumococcal Vaccines","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2012-01","conditions":"Pneumococcal Disease","enrollment":4},{"nctId":"NCT02582047","phase":"PHASE4","title":"Influenza Vaccine and Pneumococcal Vaccine","status":"COMPLETED","sponsor":"Korea University Guro Hospital","startDate":"2012-10","conditions":"Influenza, Human, Pneumococcal Infections","enrollment":224},{"nctId":"NCT02558751","phase":"EARLY_PHASE1","title":"Pneumonia Vaccine in Aging HIV Positive Individuals","status":"COMPLETED","sponsor":"University of Toledo Health Science Campus","startDate":"2013-07","conditions":"Pneumococcal Infection","enrollment":51},{"nctId":"NCT02515240","phase":"EARLY_PHASE1","title":"Immune Response to Pneumococcal Vaccination in HIV Infected Individuals","status":"COMPLETED","sponsor":"University of Toledo Health Science Campus","startDate":"2010-07","conditions":"Pneumococcal Infection","enrollment":124},{"nctId":"NCT00239694","phase":"PHASE4","title":"PPV: Pneumococcal Polysaccharide Vaccine in Older Adults","status":"COMPLETED","sponsor":"National Institute on Aging (NIA)","startDate":"2001-04","conditions":"Aging","enrollment":100},{"nctId":"NCT02492438","phase":"PHASE4","title":"13 Valent Pneumococcal Conjugate Vaccine in Chronic Dialysis Patients","status":"COMPLETED","sponsor":"AZ Sint-Jan AV","startDate":"2013-02","conditions":"Chronic Kidney Failure","enrollment":154},{"nctId":"NCT00521586","phase":"PHASE3","title":"Study Evaluating 13 Valent Pneumococcal Conjugate Vaccine With Trivalent Inactivated Influenza Vaccine","status":"COMPLETED","sponsor":"Pfizer","startDate":"2007-09","conditions":"Influenza","enrollment":1116},{"nctId":"NCT01947010","phase":"PHASE4","title":"Pneumococcal Vaccination of Crohn Patients","status":"COMPLETED","sponsor":"Statens Serum Institut","startDate":"2013-07","conditions":"Crohns Disease","enrollment":151},{"nctId":"NCT00962780","phase":"PHASE3","title":"Safety and Immunogenicity of 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) in HIV-Infected Subjects 6 Years of Age or Older Who Are Naive to Pneumococcal Vaccine","status":"COMPLETED","sponsor":"Pfizer","startDate":"2010-03","conditions":"HIV Infections, Pneumococcal Infections","enrollment":303},{"nctId":"NCT02285036","phase":"PHASE3","title":"Safety and Immunogenicity of a Newly 23-valent Pneumococcal Polysaccharide Vaccine in Chinese Adults and Children","status":"COMPLETED","sponsor":"Walvax Biotechnology Co., Ltd.","startDate":"2012-09","conditions":"Pneumococcal Infectious Diseases","enrollment":1660}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":80,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"vaccination PNEUMOVAX 23","genericName":"vaccination PNEUMOVAX 23","companyName":"Walvax Biotechnology Co., Ltd.","companyId":"walvax-biotechnology-co-ltd","modality":"Biologic","firstApprovalDate":"","aiSummary":"PNEUMOVAX 23 is a polysaccharide vaccine that stimulates the immune system to produce antibodies against 23 serotypes of Streptococcus pneumoniae. Used for Prevention of invasive pneumococcal disease in adults and children ≥2 years of age, Prevention of pneumococcal pneumonia, bacteremia, and meningitis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}